Weight loss in patients with COVID-19 and Influenza in comorbidity with NCDs: a pilot prospective clinical trial
Authors:
- Kuat OshakbayevKuat Oshakbayev
- Aigul DurmanovaADAigul Durmanova
- Alisher IdrisovAIAlisher Idrisov
- Zulfiya ZhankalovaZZZulfiya Zhankalova
- Gulnara BedelbayevaGBGulnara Bedelbayeva
- Meruyert GazaliyevaMGMeruyert Gazaliyeva
- Attila TordaiATAttila Tordai
- Altay NabiyevANAltay Nabiyev
- Bibazhar DukenbayevaBDBibazhar Dukenbayeva
Preprint
Abstract
Background: COVID and Influenza with non-communicable chronic diseases (NCDs) complicate the diagnosis, treatment, prognosis, and increase mortality rate. The aim: to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs. Methods: A 6-week open, pilot prospective clinical trial including 62 adult patients with COVID (n=27) and influenza (n=35) in comorbidity with T2D, hypertension, and NASH. Overweight in 33 patients (53.2%) with BMI 28.14±0.39 kg/m 2 , and 29 patients without overweight with BMI 23.37 ± 0.38 kg/m 2 . T2D in 26 (41.9%); Hypertension in 38 (61.3%) (incl. 12 patients with T2D); NASH in 51 patients (82.2%) (incl. 8 patients with NASH, T2D and Hypertension; 6 patients with NASH and T2D; 18 patients with NASH and Hypertension; 19 patients with only NASH). Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan. Results: The patients with overweight lost -12,4% from baseline or BMI= -4.2 kg/m 2 , and patients without overweight lost -9,14% from baseline or BMI= -2.2 kg/m 2 (−9.7±0.7 kg vs. - 6.4±0.6 kg, respectively; P P P 96.3% patients at 14-day. Systolic/diastolic BP decreased (161.3±1.31/101.6±0.85 vs. 118.3±0.46/80.89±0.66, P 9 /L) at 14-day of treatment (238.5±5.8, ×10 9 /L) ( P 9 /L) ( P P P <0.0001). The previous antidiabetic, antihypertensive, anti-inflammatory and hepatoprotective, and other symptomatic medications were adequately decreased in 2-5 days to completely stopping by 5-8 days treatment. Conclusions: The fast weight loss is clinical/laboratory benefit in treatment of patients with COVID-19 and Influenza in comorbidity with T2D, hypertension, and NASH. Trial Registration: ClinicalTrials.gov NCT05635539 . Registered 1 December 2022.Keywords
This publication has 64 references indexed in Scilit:
- Prospective associations between persistent organic pollutants and metabolic syndrome: A nested case–control studyScience of The Total Environment, 2014
- Persistent organic pollutant levels in human visceral and subcutaneous adipose tissue in obese individuals—Depot differences and dysmetabolism implicationsEnvironmental Research, 2014
- Exposure to Persistent Organic Pollutants: Relationship With Abnormal Glucose Metabolism and Visceral AdiposityDiabetes Care, 2014
- Chlorinated Persistent Organic Pollutants, Obesity, and Type 2 DiabetesEndocrine Reviews, 2014
- Diabetes mellitus and electrolyte disordersWorld Journal of Clinical Cases, 2014
- Weight change therapy as a potential treatment for end-stage ovarian carcinomaAmerican Journal of Case Reports, 2014
- Short-term weight loss attenuates local tissue inflammation and improves insulin sensitivity without affecting adipose inflammation in obese miceAmerican Journal of Physiology-Endocrinology and Metabolism, 2013
- Dietary Restriction: Critical Co-Factors to Separate Health Span from Life Span BenefitsRejuvenation Research, 2012
- Effect of 6-Month Calorie Restriction on Biomarkers of Longevity, Metabolic Adaptation, and Oxidative Stress in Overweight Individuals: A Randomized Controlled Trial—Correction2006
- Superoxide dismutase: “Positive” spectrophotometric assaysAnalytical Biochemistry, 1977